Olumiant® (baricitinib) is one of the first once-daily oral selective JAK1 and JAK2...
Vraylar (cariprazine) for the Treatment of Bipolar Disorder and Schizophrenia
Vraylar (cariprazine) is a once-daily, oral, atypical antipsychotic drug indicated for the treatment of adults with bipolar I disorder and schizophrenia.
Kognitic Launches Innovative Map Feature to its Clinical Trial Intelligence Platform
Kognitic announces the launch of an innovative feature to its platform, one which allows its customers to plot the geographic location of active clinical trials into a dynamic map.
WHO introduces human genome editing global registry
The World Health Organisation has approved the first phase of a new global registry to record the research conducted on human genome editing.
Gene therapy pipeline for neurology indications dominated by viral vectors
Of the 38 pipeline products that are currently in development stages, AAV-based delivery platforms account for 45% of these products.
Soliris – Treatment for PNH, aHUS, gMG, and NMOSD
Soliris (eculizumab) is a drug indicated for the treatment of paroxysmal nocturnal haemoglobinuria (PNH), atypical haemolytic uremic syndrome (aHUS), generalised myasthenia gravis (gMG), and neuromyelitis optica spectrum disorder (NMOSD).
Verzenio (abemaciclib) for the Treatment of Metastatic Breast Cancer
Verzenio (abemaciclib) is a cyclin-dependent kinases (CDK) 4 and 6 inhibitor indicated for the treatment of women with hormone receptor-positive (HR+) human epidermal growth factor receptor 2-negative (HER2-) advanced or metastatic breast cancer.